Nereus Raises $20M for Cancer Study

6/23/10

San Diego’s Nereus Pharmaceuticals says it has secured as much as $20 million in commitments for additional funding from its existing investors to fund a mid-stage trial of a drug candidate for treating non-small cell lung cancer. The company, which specializes in developing drugs from marine microbes, says it has enrolled 170 patients in its study of NPI-2358 (plinabulin). As Luke reported last year, Nereus previously raised $125 million. Investors are HBM BioVentures, Alta Partners, Forward Ventures, Gimv, Advent International, Pacific Venture Group, Roche Venture Fund, and Astellas Venture Management.

Bruce V. Bigelow is the editor of Xconomy San Diego. You can e-mail him at bbigelow@xconomy.com or call (619) 669-8788 Follow @

By posting a comment, you agree to our terms and conditions.